Synaptogenix, Inc. (NASDAQ:SNPX) Sees Large Growth in Short Interest

Synaptogenix, Inc. (NASDAQ:SNPX) was the target of a significant growth in short interest in the month of November. As of November 30th, there was short interest totalling 7,200 shares, a growth of 30.9% from the November 15th total of 5,500 shares. Currently, 0.5% of the company’s shares are sold short. Based on an average daily volume of 23,800 shares, the short-interest ratio is currently 0.3 days.

Synaptogenix Price Performance

Shares of NASDAQ SNPX traded up $0.01 during trading on Friday, hitting $2.69. 1,949 shares of the company traded hands, compared to its average volume of 15,190. The business’s fifty day moving average is $2.93 and its 200 day moving average is $3.53. Synaptogenix has a fifty-two week low of $2.32 and a fifty-two week high of $8.78.

Synaptogenix (NASDAQ:SNPX) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($4.58) earnings per share for the quarter, missing the consensus estimate of ($1.95) by ($2.63).

About Synaptogenix

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.